BioSyent Declares Fourth Quarter 2026 Dividend
Key Highlights
- ➤Q4 2026 dividend $0.055 per share, unchanged from Q3
- ➤Dividend payable December 15, 2026, to shareholders of record November 30
- ➤Future dividend timing, amount, and payment remain at Board discretion
Expert Statements
René C. Goehrum, President and CEO of BioSyent Inc.
“The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements.”
MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on December 15, 2026, to shareholders of record at the close of business on November 30, 2026. This fourth quarter 2026 dividend compares to a third quarter dividend of $0.055 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.
Get started
Create a free account to read the full story.
